MedPath

Randomised Controlled Trial to Assess Whether Computed Tomography Cardiac Angiography Can Improve Invasive Coronary Angiography in Bypass Surgery Patients

Not Applicable
Active, not recruiting
Conditions
Ischaemic Heart Disease
Contrast-induced Nephropathy
Interventions
Diagnostic Test: CTCA
Registration Number
NCT03736018
Lead Sponsor
Queen Mary University of London
Brief Summary

A large number of patients with symptomatic ischaemic heart disease undergo coronary artery bypass grafting (CABG) to alleviate their symptoms and improve prognosis. Given the progressive nature of coronary disease, bypass grafts can narrow or block over time, leading to chest pain and the need for further invasive coronary angiography. Invasive coronary procedures in patients with bypass grafts can be more complicated due to the variation in bypass graft ostia. This can lead to longer procedure times, with higher doses of contrast and radiation and more discomfort for the patient. The aim of this study is to see if the use of computed tomography cardiac angiography (CTCA) in patients with previous bypass grafts prior to invasive coronary angiography will help make their procedure safer and quicker.

Detailed Description

The BYPASS-CTCA trial is a single-centre, randomised controlled trial, which plans to recruit 688 patients who have had previous bypass grafts and require invasive coronary angiography over a period of 30 months.

Patients will be randomised to receive either computed tomography cardiac angiography (CTCA) prior to their invasive coronary angiogram, or invasive coronary angiography alone.

The primary endpoints will be the incidence of contrast induced nephropathy, the duration of the invasive coronary angiographic procedure and patient satisfaction. A number of secondary endpoints will also be looked at.

Findings from BYPASS-CTCA will potentially demonstrate that a CTCA prior to invasive coronary angiography in this cohort of patients reduces the incidence of contrast-induced kidney injury, the length of procedure and improves patients satisfaction. The results of this trial may influence future clinical practice guidelines in coronary artery bypass graft patients undergoing invasive coronary procedures.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
688
Inclusion Criteria
  1. Patients undergoing invasive coronary angiogram +/- percutaneous coronary Intervention
  2. Previous Coronary Artery Bypass Grafting (CABG)
  3. Aged ≥18
  4. Patients able and willing to give their written informed consent.
Exclusion Criteria
  1. Subjects presenting with ST elevation myocardial infarction, cardiogenic shock (systolic blood pressure <80 mmHg for >30 minutes, or requiring inotropes or emergency intra aortic balloon pump for hypotension treatment) or cardiopulmonary resuscitation.
  2. Subjects with eGFR <20ml/min or on renal replacement therapy.
  3. Current life-threatening condition other than vascular disease that may prevent a subject completing the study.
  4. Clinical instability including cardiogenic shock, hypotension (low blood pressure-systolic blood pressure less than 90 mmHg), sustained ventricular or atrial arrhythmia requiring intravenous medications.
  5. Inability to tolerate beta-blockers, including those with chronic obstructive pulmonary disease or asthma, complete heart block, second-degree atrioventricular block
  6. Known contrast dye allergy.
  7. Pregnancy or unknown pregnancy status.
  8. Patients considered unsuitable to participate by the research team (e.g., due to medical reasons, laboratory abnormalities, or subject's unwillingness to comply with all study related procedures).
  9. Inability or refusal to provide informed consent.
  10. Any inclusion criteria not met

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CTCA + ICACTCAComputed Tomography Cardiac Angiography (CTCA) performed prior to invasive coronary angiogram (ICA).
Primary Outcome Measures
NameTimeMethod
Procedural durationInterval between administration of local anaesthesia for obtaining vascular access and removal of the last catheter

Length of invasive coronary angiogram

Incidence of Contrast Induced Nephropathy48-72hours

Defined by Kidney Disease: Improving Global outcomes (KDIGO) criteria

Patient satisfaction4-6hours

Patient satisfaction measured by validated questionnaire

Secondary Outcome Measures
NameTimeMethod
Radiation exposureFrom time of arterial sheath insertion to removal of arterial catheters

Radiation exposure (mSv) during invasive coronary angiogram

Radial access rateFrom time of randomisation to end of invasive coronary angiogram procedure

Radial access rates during invasive coronary angiogram

Contrast amountFrom time of arterial sheath insertion to removal of arterial catheters

Contrast amount (mls) administered during invasive coronary angiogram

Angiography related complications4-6hours

Angiography related complications (coronary or aortic dissection, stroke, bleeding, vascular access complications)

Catheters usedFrom time of arterial sheath insertion to removal of arterial catheters

Number of catheters used during invasive coronary angiogram

Computed Tomography Cardiac Angiography accuracyFrom time of randomisation to end of invasive coronary angiogram procedure

Accuracy of the Computed Tomography Cardiac Angiography scan for detecting graft patency

Number of grafts not identifiedFrom time of arterial sheath insertion to removal of arterial catheters

Number of grafts not identified during invasive coronary angiogram

Cost effectiveness of computed tomography cardiac angiography12 months

Incremental Cost Effectiveness Ratio (ICER)

Trial Locations

Locations (1)

Barts Health NHS Trust

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath